Thyroid Dermopathy and Thyroid Eye Disease Associated With Hypofunctional Autoimmune Thyroid Disease With High TSI/anti-TSHR Antibodies Improved With Teprotumumab.
Document Type
Article
Publication Date
12-22-2024
Publication Title
BMJ Case Reports
Abstract
Thyroid dermopathy (TD) and thyroid eye disease (TED) are rare clinical entities in patients with hypofunctional autoimmune thyroid disease; however, these can be present in patients with thyroid-stimulating immunoglobulin (TSI)/anti-thyroid-stimulating hormone receptor (TSHR) antibodies. TED is believed to be associated with antibodies stimulating TSHRs and cross-talk with IGF-1 receptor (IGF-1R) pathway, prompting tissue proliferation. Teprotumumab (monoclonal antibody targeting IGF-1R) has been proven to improve symptoms of TED. It is proposed that TD share the same pathophysiology as TED. We present a case of a patient with hypofunctional autoimmune thyroid disease with high TSI/anti-TSHR antibodies who experienced significant improvement of symptoms of both TED and TD after six doses of teprotumumab. We postulate that further studies regarding the efficacy of teprotumumab in patients with TD are needed.
Volume
17
Issue
12
First Page
e260129
Recommended Citation
Niedzialkowska E, Pokharel A, Banka A. Thyroid dermopathy and thyroid eye disease associated with hypofunctional autoimmune thyroid disease with high TSI/anti-TSHR antibodies improved with teprotumumab. BMJ Case Rep. 2024 Dec 22;17(12):e260129. doi: 10.1136/bcr-2024-260129. PMID: 39950657.
DOI
10.1136/bcr-2024-260129
ISSN
1757-790X
PubMed ID
39950657
